Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Return on Equity (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Return on Equity for 15 consecutive years, with 4.5% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 429.0% to 4.5% in Q3 2025 year-over-year; TTM through Sep 2025 was 4.5%, a 429.0% decrease, with the full-year FY2024 number at 0.18%, down 13.0% from a year prior.
  • Return on Equity was 4.5% for Q3 2025 at Harvard Bioscience, up from 4.62% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2023 to a low of 4.62% in Q2 2025.
  • A 5-year average of 0.65% and a median of 0.08% in 2024 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: grew 13bps in 2023, then plummeted -448bps in 2025.
  • Harvard Bioscience's Return on Equity stood at 0.01% in 2021, then plummeted by -1518bps to 0.13% in 2022, then skyrocketed by 95bps to 0.01% in 2023, then plummeted by -6432bps to 0.4% in 2024, then plummeted by -1033bps to 4.5% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Return on Equity are 4.5% (Q3 2025), 4.62% (Q2 2025), and 1.82% (Q1 2025).